Contineum Therapeutics: Leadership Changes and New Directors

Ticker: CTNM · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1855175

Contineum Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyContineum Therapeutics, Inc. (CTNM)
Form Type8-K
Filed DateMar 17, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, board-of-directors, executive-compensation

TL;DR

Contineum shakes up exec team & board, names Epstein & Kelly as new directors.

AI Summary

Contineum Therapeutics, Inc. announced on March 14, 2025, the departure of Dr. Jonathan Leaman as Chief Medical Officer. The company also announced the election of Dr. David Epstein and Ms. Sarah Kelly to its Board of Directors, effective March 14, 2025. Additionally, the company entered into a new compensatory arrangement with its Chief Executive Officer, Dr. Michael Stebel.

Why It Matters

These changes in leadership and board composition could signal a shift in the company's strategic direction or operational focus.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

  • Contineum Therapeutics, Inc. (company) — Registrant
  • Dr. Jonathan Leaman (person) — Departing Chief Medical Officer
  • Dr. David Epstein (person) — Newly Elected Director
  • Ms. Sarah Kelly (person) — Newly Elected Director
  • Dr. Michael Stebel (person) — Chief Executive Officer
  • March 14, 2025 (date) — Effective date of changes

FAQ

Who has departed from Contineum Therapeutics?

Dr. Jonathan Leaman has departed as Chief Medical Officer.

Who has been elected to the Board of Directors?

Dr. David Epstein and Ms. Sarah Kelly have been elected to the Board of Directors.

When were the board changes effective?

The election of Dr. David Epstein and Ms. Sarah Kelly to the Board of Directors was effective March 14, 2025.

What other item is reported in this 8-K?

The company also entered into a new compensatory arrangement with its Chief Executive Officer, Dr. Michael Stebel.

What is the former name of Contineum Therapeutics?

The former name of Contineum Therapeutics was Pipeline Therapeutics, Inc.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 by Dr. Jonathan Leaman regarding Contineum Therapeutics, Inc. (CTNM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.